

BUYTP: Rs 325 | ▲ 45%

MAYUR UNIQUOTERS

Textiles

13 November 2019

Demand slowdown deepens

Mayur Uniquoters' (MUNI) Q2FY20 standalone revenue declined 16% YoY amid a continued slowdown in user industries (footwear, auto) where volumes dropped 20% YoY. Standalone operating margins contracted 185bps YoY to 16.8% due to higher employee and other expenses, which offset gross margin gains of 140bps. EBITDA/PBT were down 24%/27% YoY. We cut FY20-FY22 PAT estimates by 7-12% due to the deepening downturn in user industries. Rolling valuations over, we have a Sep'20 TP of Rs 325 (Rs 335 earlier).

Arun Baid research@bobcaps.in

Continued weakness in user industries dents revenue: MUNI reported a 16% YoY decline in standalone revenue to Rs 1.2bn for Q2FY20, with volumes contracting 20% YoY. Volumes sagged across verticals – the auto replacement segment was down 42% and footwear 37%. Management sees a bleak near-term demand outlook pending recovery in auto sales. The new PU plant will start trial production in November and commercial production from December this year.

Operating margins contract: Despite gross margin expansion (+140bps), MUNI reported a 185bps drop in standalone operating margins to 16.8% due to higher employee cost (+90bps) and other expenditure (+240bps) – this dragged EBITDA/PBT down 24%/27% YoY. Gross margins expanded due to a better product mix whereas other expenses increased due to a Rs 20mn provision for bad debts and another Rs 20mn in fair value adjustment.

Maintain BUY: In light of the sustained downturn in end-user verticals, we cut FY20-FY22 PAT estimates by 7-12%. Maintain BUY with a revised Sep'20 TP of Rs 325 (vs. Rs 335), set at an unchanged 15x one-year forward P/E.

| Ticker/Price | MUNI IN/Rs 224 |
|------------------|----------------|
| Market cap | US\$ 140.7mn |
| Shares o/s | 45mn |
| 3M ADV | US\$ 0.2mn |
| 52wk high/low | Rs 406/Rs 202 |
| Promoter/FPI/DII | 61%/13%/25% |
| C NCE | |

Source: NSE

STOCK PERFORMANCE



Source: NSE

KEY FINANCIALS

| Y/E 31 Mar | FY18A | FY19A | FY20E | FY21E | FY22E |
|-------------------------|-------|--------|-------|-------|-------|
| Total revenue (Rs mn) | 5,700 | 5,913 | 5,399 | 6,723 | 7,816 |
| EBITDA (Rs mn) | 1,500 | 1,292 | 942 | 1,338 | 1,579 |
| Adj. net profit (Rs mn) | 905 | 727 | 688 | 892 | 1,079 |
| Adj. EPS (Rs) | 20.0 | 16.0 | 15.2 | 19.7 | 23.8 |
| Adj. EPS growth (%) | 21.9 | (19.7) | (5.3) | 29.6 | 21.0 |
| Adj. ROAE (%) | 21.7 | 15.0 | 12.7 | 14.9 | 16.2 |
| Adj. P/E (x) | 11.2 | 14.0 | 14.7 | 11.4 | 9.4 |
| EV/EBITDA (x) | 5.9 | 6.5 | 8.8 | 6.2 | 5.0 |





FIG 1 – STANDALONE QUARTERLY PERFORMANCE

| (Rs mn) | Q2FY20 | Q2FY19 | Y ₀ Y (%) | Q1FY20 | Q ₀ Q (%) |
|-----------------------------|--------|--------|----------------------|--------|----------------------|
| Total revenues | 1,242 | 1,477 | (15.9) | 1,282 | (3.1) |
| Total raw material consumed | 777 | 945 | (17.8) | 790 | (1.6) |
| % of sales | 62.6 | 64.0 | (142bps) | 61.6 | 95bps |
| Employee expense | 75 | 76 | (1.2) | 81 | (7.9) |
| % of sales | 6.0 | 5.1 | 90bps | 6.3 | (32bps) |
| Other expense | 181 | 181 | 0.4 | 160 | 13.7 |
| % of sales | 14.6 | 12.2 | 238bps | 12.4 | 215bps |
| Total expenditure | 1,033 | 1,201 | (14.0) | 1,031 | 0.2 |
| EBITDA | 209 | 276 | (24.3) | 251 | (16.9) |
| % of sales | 16.8 | 18.7 | (186bps) | 19.6 | (279bps) |
| Depreciation | 44.3 | 44 | (0.2) | 43 | 2.6 |
| Other income | 51.6 | 68 | (24.5) | 37 | 40.9 |
| Interest cost | 1.4 | 5.5 | (74.5) | 1.9 | (25.6) |
| PBT | 215 | 294 | (27.0) | 243 | (11.6) |
| Taxes | 15 | 94 | (84.4) | 84 | (82.6) |
| Effective tax rate (%) | 6.8 | 32.0 | (2,514bps) | 34.7 | (2,789bps) |
| RPAT | 200 | 200 | (0.1) | 159 | 26.2 |


Source: Company, BOBCAPS Research

FIG 2 - CONSOLIDATED QUARTERLY PERFORMANCE


| (Rs mn) | Q2FY20 | Q2FY19 | Y ₀ Y (%) | Q1FY20 | Q ₀ Q (%) |
|-----------------------------|--------|--------|----------------------|--------|----------------------|
| Total revenues | 1,309 | 1,609 | (18.7) | 1,274 | 2.8 |
| Total raw material consumed | 796 | 1,001 | (20.5) | 822 | (3.2) |
| % of sales | 64.1 | 67.8 | (365bps) | 64.1 | (3bps) |
| Employee expense | 79 | 77 | 1.7 | 84 | (6.9) |
| % of sales | 6.3 | 5.2 | 110bps | 6.6 | (26bps) |
| Other expense | 205 | 197 | 4.3 | 193 | 6.5 |
| % of sales | 16.5 | 13.3 | 321bps | 15.0 | 150bps |
| Total expenditure | 1,080 | 1,275 | (15.3) | 1,099 | (1.7) |
| EBITDA | 229 | 334 | (31.5) | 174 | 31.5 |
| % of sales | 17.5 | 20.8 | (329bps) | 13.7 | 382bps |
| Depreciation | 44.3 | 44 | (0.2) | 43 | 2.6 |
| Other income | 52.4 | 63 | (16.9) | 37 | 42.9 |
| Interest cost | 1.7 | 6 | (69.9) | 2 | (21.4) |
| PBT | 235 | 347 | (32.3) | 165 | 42.2 |
| Taxes | 16 | 105 | (84.5) | 68 | (76.2) |
| Effective tax rate (%) | 6.9 | 30.1 | (2,319bps) | 41.1 | (3,425bps) |
| RPAT | 219 | 243 | (9.8) | 97 | 125.0 |




STANDALONE QUARTERLY TRENDS




Source: Company, BOBCAPS Research




Source: Company, BOBCAPS Research





Source: Company, BOBCAPS Research

FIG 6 - VOLUMES



Source: Company, BOBCAPS Research

Earnings call highlights

- MUNI has seen a sharp drop in demand from both its major client industries,
 i.e. automotive (including replacement market) and footwear the latter due to tight liquidity conditions.
- Automotive OEMs have started to ask for discounts but the company has been able to fend them off by citing its premium products.
- Additions to the automotive OEM customer base helped restrict the revenue decline from the auto segment to ~10% in Q2. MG Motors was one of the additions in the domestic segment and MUNI is now the sole supplier.
- Management expects to start supplies to Mercedes Benz, Europe, from Q3FY21.
- South India forms ~85% of footwear revenues. Due to the continued slowdown in the footwear market, MUNI has been compelled to take a 3-3.5% price reduction.



- Efforts are underway to cut costs given the difficult external environment. The company has laid off 120 employees during the year.
- As per management, raw material (PVC resin) cost remains elevated but plasticizer cost is stable. The higher RM cost cannot be passed on due to tepid demand conditions.
- The company has provided for ~Rs 20mn due from an automotive OEM and also ~Rs 20mn as fair valuation adjustment (both in other expense) during the quarter.
- PU plant dry runs have already begun as most of the machinery has been installed. The company plans to do trial runs by end-November and start commercial production by end-December.
- The PU plant has a capacity to install four lines of 0.5mn mtrs each. The company will initially start with one line. PVC line expansion is on hold due to the weak market conditions.
- MUNI has opted for the new tax regime and its tax rate will be ~25.2% going ahead.



Valuation methodology

MUNI is the market leader in India's PVC synthetic leather industry and also caters to US auto OEMs – a market which no other domestic company has managed to penetrate. The company is entering the PU synthetic leather market, which is primarily import-oriented, with the commencement of a plant in Madhya Pradesh in Dec'19.

We cut FY20-FY22 PAT estimates by 7-12% due to a deepening downturn in the auto and footwear end-user industries. Rolling valuations over, we have a revised Sep'20 target price of Rs 325 (Rs 335 earlier), set at an unchanged 15x one-year forward P/E multiple. Maintain BUY.

FIG 7 - REVISED ESTIMATES

| (D) | New | | Old | | | Change (%) | | | |
|----------|-------|-------|-------|-------|-------|------------|--------|-------|-------|
| (Rs mn) | FY20 | FY21 | FY22 | FY20 | FY21 | FY22 | FY20 | FY21 | FY22 |
| Revenues | 5,399 | 6,723 | 7,816 | 5,780 | 7,132 | 8,267 | (6.6) | (5.7) | (5.5) |
| EBITDA | 942 | 1,338 | 1,579 | 1,168 | 1,448 | 1,695 | (19.3) | (7.6) | (6.8) |
| PAT | 688 | 892 | 1,079 | 785 | 969 | 1,160 | (12.4) | (7.9) | (6.9) |

Source: Company, BOBCAPS Research

FIG 8 - RELATIVE STOCK PERFORMANCE



Source: NSE

Key risks

- Failure/delays in commissioning of PU/PVC plant: Delays in setting up the proposed PU/PVC facilities or a failure to do so could adversely affect growth prospects.
- Continued slowdown in end-user industries: A prolonged slowdown in MUNI's major end-user industries of footwear and auto will adversely affect the company's growth prospects.



- Volatility in raw material prices: A majority of MUNI's raw material is linked to crude prices. Any abnormal increase/decrease in crude prices can hurt the company's profitability.
- Competition from unorganised players: MUNI operates in a highly fragmented market that has several unorganised players – these may pose stiff competition and erode the company's growth



FINANCIALS

Income Statement

| Y/E 31 Mar (Rs mn) | FY18A | FY19A | FY20E | FY21E | FY22E |
|--------------------------------|-------|-------|-------|-------|-------|
| Total revenue | 5,700 | 5,913 | 5,399 | 6,723 | 7,816 |
| EBITDA | 1,500 | 1,292 | 942 | 1,338 | 1,579 |
| Depreciation | (171) | (180) | (193) | (277) | (299) |
| EBIT | 1,329 | 1,112 | 749 | 1,061 | 1,279 |
| Net interest income/(expenses) | (14) | (9) | (13) | (15) | (15) |
| Other income/(expenses) | 67 | 42 | 183 | 146 | 178 |
| Exceptional items | 0 | 0 | 0 | 0 | 0 |
| EBT | 1,382 | 1,145 | 920 | 1,192 | 1,443 |
| Income taxes | (477) | (418) | (232) | (300) | (364) |
| Extraordinary items | 64 | 169 | 0 | 0 | 0 |
| Min. int./Inc. from associates | 0 | 0 | 0 | 0 | 0 |
| Reported net profit | 969 | 896 | 688 | 892 | 1,079 |
| Adjustments | (64) | (169) | 0 | 0 | 0 |
| Adjusted net profit | 905 | 727 | 688 | 892 | 1,079 |

Balance Sheet

| Y/E 31 Mar (Rs mn) | FY18A | FY19A | FY20E | FY21E | FY22E |
|--------------------------------|-------|-------|-------|-------|-------|
| Accounts payables | 610 | 592 | 562 | 682 | 792 |
| Other current liabilities | 77 | 151 | 148 | 147 | 171 |
| Provisions | 29 | 30 | 27 | 34 | 39 |
| Debt funds | 59 | 217 | 50 | 50 | 50 |
| Other liabilities | 52 | 32 | 32 | 32 | 32 |
| Equity capital | 226 | 226 | 226 | 226 | 226 |
| Reserves & surplus | 4,270 | 4,953 | 5,435 | 6,059 | 6,814 |
| Shareholders' fund | 4,496 | 5,179 | 5,661 | 6,285 | 7,041 |
| Total liabilities and equities | 5,322 | 6,201 | 6,480 | 7,229 | 8,125 |
| Cash and cash eq. | 283 | 203 | 66 | 248 | 245 |
| Accounts receivables | 1,031 | 890 | 873 | 1,050 | 1,221 |
| Inventories | 965 | 1,229 | 1,109 | 1,253 | 1,435 |
| Other current assets | 127 | 337 | 251 | 276 | 321 |
| Investments | 1,562 | 1,870 | 1,800 | 2,100 | 2,650 |
| Net fixed assets | 1,310 | 1,254 | 1,961 | 1,884 | 1,835 |
| CWIP | 19 | 393 | 393 | 393 | 393 |
| Intangible assets | 26 | 26 | 26 | 26 | 26 |
| Deferred tax assets, net | 0 | 0 | 0 | 0 | 0 |
| Other assets | 0 | 0 | 0 | 0 | 0 |
| Total assets | 5,322 | 6,201 | 6,480 | 7,229 | 8,125 |



Cash Flows

| Y/E 31 Mar (Rs mn) | FY18A | FY19A | FY20E | FY21E | FY22E |
|------------------------------|-------|-------|-------|-------|-------|
| Net income + Depreciation | 1,140 | 1,076 | 881 | 1,169 | 1,379 |
| Interest expenses | 14 | 9 | 13 | 15 | 15 |
| Non-cash adjustments | 0 | 0 | 0 | 0 | 0 |
| Changes in working capital | (135) | (276) | 186 | (220) | (258) |
| Other operating cash flows | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | 1,019 | 809 | 1,080 | 964 | 1,136 |
| Capital expenditures | (204) | (498) | (900) | (200) | (250) |
| Change in investments | (365) | (308) | 70 | (300) | (550) |
| Other investing cash flows | 5 | 0 | 0 | 0 | 0 |
| Cash flow from investing | (564) | (806) | (830) | (500) | (800) |
| Equities issued/Others | (250) | 0 | 0 | 0 | 0 |
| Debt raised/repaid | (61) | 159 | (167) | 0 | 0 |
| Interest expenses | (14) | (9) | (13) | (15) | (15) |
| Dividends paid | (77) | (177) | (206) | (268) | (324) |
| Other financing cash flows | 10 | (56) | 0 | 0 | 0 |
| Cash flow from financing | (392) | (83) | (386) | (283) | (339) |
| Changes in cash and cash eq. | 63 | (80) | (136) | 181 | (3) |
| Closing cash and cash eq. | 283 | 203 | 66 | 248 | 245 |

Per Share

| Y/E 31 Mar (Rs) | FY18A | FY19A | FY20E | FY21E | FY22E |
|----------------------|-------|-------|-------|-------|-------|
| Reported EPS | 21.4 | 19.8 | 15.2 | 19.7 | 23.8 |
| Adjusted EPS | 20.0 | 16.0 | 15.2 | 19.7 | 23.8 |
| Dividend per share | 1.2 | 3.3 | 3.8 | 4.9 | 6.0 |
| Book value per share | 99.3 | 114.4 | 125.0 | 138.8 | 155.5 |

Valuations Ratios

| Y/E 31 Mar (x) | FY18A | FY19A | FY20E | FY21E | FY22E |
|----------------|-------|-------|-------|-------|-------|
| EV/Sales | 1.6 | 1.4 | 1.5 | 1.2 | 1.0 |
| EV/EBITDA | 5.9 | 6.5 | 8.8 | 6.2 | 5.0 |
| Adjusted P/E | 11.2 | 14.0 | 14.7 | 11.4 | 9.4 |
| P/BV | 2.3 | 2.0 | 1.8 | 1.6 | 1.4 |

DuPont Analysis

| Y/E 31 Mar (%) | FY18A | FY19A | FY20E | FY21E | FY22E |
|---------------------------------|-------|-------|-------|-------|-------|
| Tax burden (Net profit/PBT) | 65.5 | 63.5 | 74.8 | 74.8 | 74.8 |
| Interest burden (PBT/EBIT) | 104.0 | 103.0 | 122.8 | 112.4 | 112.7 |
| EBIT margin (EBIT/Revenue) | 23.3 | 18.8 | 13.9 | 15.8 | 16.4 |
| Asset turnover (Revenue/Avg TA) | 113.6 | 102.6 | 85.1 | 98.1 | 101.8 |
| Leverage (Avg TA/Avg Equity) | 1.2 | 1.2 | 1.2 | 1.1 | 1.2 |
| Adjusted ROAE | 21.7 | 15.0 | 12.7 | 14.9 | 16.2 |
| 6 6 86861868 | | | | | |

Source: Company, BOBCAPS Research | Note: TA = Total Assets



Ratio Analysis

| Y/E 31 Mar | FY18A | FY19A | FY20E | FY21E | FY22E |
|-----------------------------------|-------|--------|--------|-------|-------|
| YoY growth (%) | | | | | |
| Revenue | 18.3 | 3.7 | (8.7) | 24.5 | 16.3 |
| EBITDA | 17.4 | (13.9) | (27.1) | 42.0 | 18.0 |
| Adjusted EPS | 21.9 | (19.7) | (5.3) | 29.6 | 21.0 |
| Profitability & Return ratios (%) | | | | | |
| EBITDA margin | 26.3 | 21.9 | 17.5 | 19.9 | 20.2 |
| EBIT margin | 23.3 | 18.8 | 13.9 | 15.8 | 16.4 |
| Adjusted profit margin | 15.9 | 12.3 | 12.7 | 13.3 | 13.8 |
| Adjusted ROAE | 21.7 | 15.0 | 12.7 | 14.9 | 16.2 |
| ROCE | 20.4 | 14.2 | 10.1 | 13.2 | 14.3 |
| Working capital days (days) | | | | | |
| Receivables | 64 | 59 | 60 | 52 | 53 |
| Inventory | 101 | 112 | 128 | 103 | 101 |
| Payables | 47 | 47 | 47 | 42 | 43 |
| Ratios (x) | | | | | |
| Gross asset turnover | 3.1 | 3.5 | 2.5 | 2.5 | 2.6 |
| Current ratio | 3.2 | 3.1 | 3.0 | 3.2 | 3.1 |
| Net interest coverage ratio | 96.9 | 128.4 | 59.9 | 70.7 | 85.3 |
| Adjusted debt/equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |



Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

ADD - Expected return from >+5% to +15%

REDUCE - Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

HISTORICAL RATINGS AND TARGET PRICE: MAYUR UNIQUOTERS (MUNI IN)



B - Buy, A - Add, R - Reduce, S - Sell

Rating distribution

As of 31 October 2019, out of 79 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 48 have BUY ratings, 18 are rated ADD, 7 are rated REDUCE and 6 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations



expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.